EUCAST technical note on posaconazole

Clin Microbiol Infect. 2011 Nov;17(11):E16-7. doi: 10.1111/j.1469-0691.2011.03646.x. Epub 2011 Sep 16.

Abstract

The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for posaconazole for Candida spp. This Technical Note is based on the EUCAST posaconazole rationale document (available on the EUCAST website: http://www.eucast.org). Species-specific breakpoints for C. albicans, C. parapsilosis and C. tropicalis are S: MIC ≤0.06 mg/L, R: MIC >0.06 mg/L. There are insufficient data to set breakpoints for C. glabrata and C. krusei as well as non-species-related breakpoints. The breakpoints are based upon pharmacokinetic data, epidemiological cut-off values and clinical experience. Breakpoints will be reviewed regularly.

MeSH terms

  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / pharmacology*
  • Candida / drug effects*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Triazoles / pharmacokinetics
  • Triazoles / pharmacology*

Substances

  • Antifungal Agents
  • Triazoles
  • posaconazole